Boehringer Ingelheim is paying 1.18 billion euros ($1.5 billion) for Swiss-based NBE Therapeutics as the German drugmaker is adding pipeline candidates including a drug in early trials against triple-negative breast cancer and lung cancer.

Paris-based Ipsen secured Fast Track designation from the U.S. Food and Drug Administration for Onivyde (irinotecan liposome injection) for study patients with small cell lung cancer (SCLC) who progressed following a first-line platinum-based regimen.

Urovant Sciences and Genmab reported disappointing clinical trial announcements.

ADC Therapeutics SA announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration for loncastuximab tesirine (Lonca) for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

Immunomedics Inc.’s cancer drug Trodelvy, which received accelerated U.S. regulatory approval in April 2020, extended survival time in previously treated patients with an advanced form of breast cancer in a clinical trial.

Seattle Genetics’ shares rocketed after news broke of Merck making a major investment into the Bothwell, Washington-based company via two strategic oncology deals.

Gilead Sciences Inc. and Immunomedics announced that the companies entered into a definitive agreement pursuant to which Gilead will acquire Immunomedics for $88.00 per share in cash.

AstraZeneca inked a global development and commercialization deal with Daiichi Sankyo for DS-1062, a trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate for multiple cancer types.

A panel of the European Medicines Agency recommended approving GlaxoSmithKline’s experimental treatment for a common form of blood cancer, days after a similar nod from a U.S. Food and Drug Administration panel.

An independent panel to the U.S. Food and Drug Administration voted in favor of approving GlaxoSmithKline’s experimental treatment for a common form of blood cancer, saying the benefits of the treatment outweigh the risks.